Nicole Liffrig Molife is healthcare and life sciences counsel in the Washington, D.C. office of Latham & Watkins. Ms. Liffrig Molife provides healthcare regulatory advice on transactions to a diverse set of early-stage and established healthcare and life sciences clients throughout the industry, including:
- Pharmaceutical and biotechnology manufacturers
- Medical device manufacturers
- Digital health and health IT companies
- Hospitals and academic medical centers
- Ambulatory surgery centers, urgent care, remote monitoring and diagnostic imaging centers
- Dialysis companies
- Hospices and home health agencies
- Health management companies
- Industry trade associations, and professional societies on regulatory compliance and business transactions.
- Long-term care and senior living providers
Ms. Liffrig Molife’s practice focuses on healthcare transactions and regulatory counseling matters. She advises clients on healthcare regulatory, compliance and business considerations that clients in the healthcare and life sciences industry face in transactions and contractual arrangements. These matters have included mergers, acquisitions, financings, securities offerings, joint ventures, contractual affiliations and other business agreements and consulting and service agreements involving a wide variety of healthcare and life sciences companies. She handles a range of healthcare regulatory matters including fraud and abuse counseling, voluntary self-disclosures, and investigations involving the Stark Law, the Federal Anti-Kickback Statute, the False Claims Act, Medicare and Medicaid regulations and policies.
Ms. Liffrig Molife writes and speaks frequently on a variety of healthcare and life sciences topics, including healthcare compliance risks and regulatory structural considerations arising in healthcare transactions, fraud and abuse risks in Health IT agreements, compliance with the Stark Law, contract negotiation and due diligence strategies, and Medicare coverage and reimbursement matters. Recent thought leadership includes:
- "The Future of Meaningful Use: CMS’s Stage 3 EHR Incentive Program Proposed Rule," Bloomberg BNA: Health IT Law & Industry Report (June 29, 2015)